Reuters -- A strategic player looks set to clinch Ratiopharm after a raft of private equity bidders dropped out of the race to bid for the German generic drugs maker, sources familiar with the matter said Wednesday.
Reuters -- A strategic player looks set to clinch Ratiopharm after a raft of private equity bidders dropped out of the race to bid for the German generic drugs maker, sources familiar with the matter said Wednesday.
